CentryMed
Latest round
- Series B
Last raised
- Dec 2020
Total raised
- $22M
Investors
- 8
About CentryMed
Based in Hangzhou, China and established in 2017, dba CentryMed, is a biotechnology company specializing in the R&D and production of targeted drugs for anti-malignant tumors and autoimmune diseases. The company was founded by Dr.S. National Cancer Institute (NCI). In 2018, the company established a subsidiary in the United States. In 2022, CentryMed completed the Phase I clinical trial of DNV3, one of its core pipeline products targeting advanced/metastatic solid tumors and lymphomas. In September 2025, the company was converted into a joint stock company. In May 2026, CentryMed submitted an IPO application to Hong Kong Exchanges and Clearing (HKEX), preparing for its upcoming IPO. CentryMed focuses on the development of targeted drugs for anti-malignant tumors and autoimmune diseases based on T-cell engager (TCE) and T-cell modulator (TCM) therapies. The company has developed several pipeline products including DNV3, an advanced TCM targeting lymphocyte activation gene 3 (LAG-3), applied in treating advanced/metastatic solid tumors and lymphomas, and SMET12, a TCE drug candidate targeting EGFR-positive advanced solid tumors. The company generates revenue through developing candidate drugs for the treatment of solid tumors.
Who invested in CentryMed
8 investors across 2 rounds
See all investors in CentryMed
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about CentryMed
Who invested in CentryMed?
CentryMed has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CentryMed raised?
CentryMed has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did CentryMed last raise money?
CentryMed's most recent round on record is a Series B, in Dec 2020.
What does CentryMed do?
Based in Hangzhou, China and established in 2017, dba CentryMed, is a biotechnology company specializing in the R&D and production of targeted drugs for anti-malignant tumors and autoimmune diseases.
Where is CentryMed headquartered?
CentryMed is headquartered in Hangzhou, China.
Which VCs invest in companies like CentryMed?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at CentryMed's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like CentryMed? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.